Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 122

1.

HIV pre-exposure prophylaxis for people who inject drugs: a review of current results and an agenda for future research.

Escudero DJ, Lurie MN, Kerr T, Howe CJ, Marshall BD.

J Int AIDS Soc. 2014 Mar 27;17:18899. doi: 10.7448/IAS.17.1.18899. Review.

2.

Acceptability of HIV Pre-exposure Prophylaxis (PREP) Among People Who Inject Drugs (PWID) in a Canadian Setting.

Escudero DJ, Kerr T, Wood E, Nguyen P, Lurie MN, Sued O, Marshall BD.

AIDS Behav. 2015 May;19(5):752-7. doi: 10.1007/s10461-014-0867-z.

3.

Pre-exposure prophylaxis to prevent HIV infection: current status, future opportunities and challenges.

Krakower DS, Mayer KH.

Drugs. 2015 Feb;75(3):243-51. doi: 10.1007/s40265-015-0355-4. Review.

4.

The potential uses of preexposure prophylaxis for HIV prevention among people who inject drugs.

Baral SD, Strömdahl S, Beyrer C.

Curr Opin HIV AIDS. 2012 Nov;7(6):563-8. doi: 10.1097/COH.0b013e328358e49e. Review.

5.

The impact of adherence to preexposure prophylaxis on the risk of HIV infection among people who inject drugs.

Martin M, Vanichseni S, Suntharasamai P, Sangkum U, Mock PA, Leethochawalit M, Chiamwongpaet S, Curlin ME, Na-Pompet S, Warapronmongkholkul A, Kittimunkong S, Gvetadze RJ, McNicholl JM, Paxton LA, Choopanya K; Bangkok Tenofovir Study Group..

AIDS. 2015 Apr 24;29(7):819-24. doi: 10.1097/QAD.0000000000000613.

PMID:
25985403
6.

Factors associated with the uptake of and adherence to HIV pre-exposure prophylaxis in people who have injected drugs: an observational, open-label extension of the Bangkok Tenofovir Study.

Martin M, Vanichseni S, Suntharasamai P, Sangkum U, Mock PA, Chaipung B, Worrajittanon D, Leethochawalit M, Chiamwongpaet S, Kittimunkong S, Gvetadze RJ, McNicholl JM, Paxton LA, Curlin ME, Holtz TH, Samandari T, Choopanya K; Bangkok Tenofovir Study Group..

Lancet HIV. 2016 Nov 17. pii: S2352-3018(16)30207-7. doi: 10.1016/S2352-3018(16)30207-7. [Epub ahead of print]

PMID:
27866873
7.

The promises and challenges of pre-exposure prophylaxis as part of the emerging paradigm of combination HIV prevention.

Cáceres CF, Koechlin F, Goicochea P, Sow PS, O'Reilly KR, Mayer KH, Godfrey-Faussett P.

J Int AIDS Soc. 2015 Jul 20;18(4 Suppl 3):19949. doi: 10.7448/IAS.18.4.19949.

8.

Vital Signs: Estimated Percentages and Numbers of Adults with Indications for Preexposure Prophylaxis to Prevent HIV Acquisition--United States, 2015.

Smith DK, Van Handel M, Wolitski RJ, Stryker JE, Hall HI, Prejean J, Koenig LJ, Valleroy LA.

MMWR Morb Mortal Wkly Rep. 2015 Nov 27;64(46):1291-5. doi: 10.15585/mmwr.mm6446a4.

9.

Commentary: the value of PrEP for people who inject drugs.

Coleman RL, McLean S.

J Int AIDS Soc. 2016 Oct 18;19(7(Suppl 6)):21112. doi: 10.7448/IAS.19.7.21112.

10.

HIV pre-exposure prophylaxis and health and community systems in the Global South: Thailand case study.

Colby D, Srithanaviboonchai K, Vanichseni S, Ongwandee S, Phanuphak N, Martin M, Choopanya K, Chariyalertsak S, van Griensven F.

J Int AIDS Soc. 2015 Jul 20;18(4 Suppl 3):19953. doi: 10.7448/IAS.18.4.19953.

11.

Tailored combination prevention packages and PrEP for young key populations.

Pettifor A, Nguyen NL, Celum C, Cowan FM, Go V, Hightow-Weidman L.

J Int AIDS Soc. 2015 Feb 26;18(2 Suppl 1):19434. doi: 10.7448/IAS.18.2.19434.

12.

Barriers to HIV treatment among people who use injection drugs: implications for 'treatment as prevention'.

Milloy MJ, Montaner J, Wood E.

Curr Opin HIV AIDS. 2012 Jul;7(4):332-8. doi: 10.1097/COH.0b013e328354bcc8. Review.

PMID:
22576468
13.

Rethinking HIV prevention to prepare for oral PrEP implementation for young African women.

Celum CL, Delany-Moretlwe S, McConnell M, van Rooyen H, Bekker LG, Kurth A, Bukusi E, Desmond C, Morton J, Baeten JM.

J Int AIDS Soc. 2015 Jul 20;18(4 Suppl 3):20227. doi: 10.7448/IAS.18.4.20227.

14.

Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial.

Choopanya K, Martin M, Suntharasamai P, Sangkum U, Mock PA, Leethochawalit M, Chiamwongpaet S, Kitisin P, Natrujirote P, Kittimunkong S, Chuachoowong R, Gvetadze RJ, McNicholl JM, Paxton LA, Curlin ME, Hendrix CW, Vanichseni S; Bangkok Tenofovir Study Group..

Lancet. 2013 Jun 15;381(9883):2083-90. doi: 10.1016/S0140-6736(13)61127-7.

PMID:
23769234
15.

The cost and impact of scaling up pre-exposure prophylaxis for HIV prevention: a systematic review of cost-effectiveness modelling studies.

Gomez GB, Borquez A, Case KK, Wheelock A, Vassall A, Hankins C.

PLoS Med. 2013;10(3):e1001401. doi: 10.1371/journal.pmed.1001401. Review.

16.

The promise of pre-exposure prophylaxis with antiretroviral drugs to prevent HIV transmission: a review.

Hankins CA, Dybul MR.

Curr Opin HIV AIDS. 2013 Jan;8(1):50-8. doi: 10.1097/COH.0b013e32835b809d. Review.

PMID:
23201856
18.

PrEP implementation: moving from trials to policy and practice.

Cáceres CF, O'Reilly KR, Mayer KH, Baggaley R.

J Int AIDS Soc. 2015 Jul 20;18(4 Suppl 3):20222. doi: 10.7448/IAS.18.4.20222.

19.

Ethical issues in HIV prevention research with people who inject drugs.

Sugarman J, Rose SM, Metzger D.

Clin Trials. 2014 Apr;11(2):239-45. doi: 10.1177/1740774513505157.

20.

Tenofovir-based oral preexposure prophylaxis prevents HIV infection among women.

Thomson KA, Baeten JM, Mugo NR, Bekker LG, Celum CL, Heffron R.

Curr Opin HIV AIDS. 2016 Jan;11(1):18-26. doi: 10.1097/COH.0000000000000207. Review.

Items per page

Supplemental Content

Support Center